To elucidate the impact of human exposure to engineered nanomaterials, advanced in vitro models are a valid non-animal alternative. Despite significant gains over the last decade, implementation of these approaches remains limited. This work discusses the current state-of-the-art and how future developments can lead to advanced in vitro models better supporting nano-hazard assessment.
No takes yet. Share an insight, caveat, or question.
Clift et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: